These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20204543)

  • 21. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
    Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
    Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
    Deenik W; van der Holt B; Janssen JJ; Chu IW; Valk PJ; Ossenkoppele GJ; van der Heiden IP; Sonneveld P; van Schaik RH; Cornelissen JJ
    Blood; 2010 Dec; 116(26):6144-5; author reply 6145-6. PubMed ID: 21183698
    [No Abstract]   [Full Text] [Related]  

  • 23. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
    Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
    Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
    Chen WW; Meng FY; Zhong JS; Yin CX; Wang ZX
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1405-8. PubMed ID: 22883199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
    Wang D; Ke XY; Wang J; Xu F; Hu YF
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1384-8. PubMed ID: 17785057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
    Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
    Dressman MA; Malinowski R; McLean LA; Gathmann I; Capdeville R; Hensley M; Polymeropoulos MH;
    Clin Cancer Res; 2004 Apr; 10(7):2265-71. PubMed ID: 15073101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse].
    Yang ZY; Zhang YS; Liang CX; Zhou ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1644-1648. PubMed ID: 30501698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
    Agarwal A; Eide CA; Harlow A; Corbin AS; Mauro MJ; Druker BJ; Corless CL; Heinrich MC; Deininger MW
    Leukemia; 2008 Dec; 22(12):2269-72. PubMed ID: 18509354
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib.
    Kassogue Y; Quachouh M; Dehbi H; Quessar A; Benchekroun S; Nadifi S
    Med Oncol; 2014 Jul; 31(7):47. PubMed ID: 24913811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.